Levomepromazine |
Methotrimeprazine |
Levoprome |
RP-7044 |
XP03 |
Tisercin |
Nirvan |
CL-39743 |
CL-36467 |
SK&F-5116 |
Riva-meprazine 5mg Tablets |
Riva-meprazine 50mg Tablets |
Riva-meprazine 25mg Tablets |
PMS-methotrimeprazine |
Nozinan Tab 50mg |
Nozinan Tab 2mg |
Nozinan Tab 25mg |
Nozinan Liq 40mg/ml |
Nozinan Inj 25mg/ml |
Nozinan 5mg/ml |
Nozinan 5mg Tab |
Nozinan |
Novo Meprazine Tab 5mg |
Novo Meprazine Tab 25mg |
Nov Meprazine Tab 50mg |
Nosinan |
Neurocil |
Methotrimeprazine-50 |
Methotrimeprazine-5 |
Methotrimeprazine-25 |
Methotrimeprazine-2 |
Methoprazine |
60-99-1 |
Levomepromazinum |
Levomepromazina |
2-Methoxytrimeprazine |
(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine |
(-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine |
DB01403 |
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-METHOXY-N,N,B-TRIMETHYL-, (.BETA.R)- |
(R)-(-)-2-METHOXY-N,N,BETA-TRIMETHYL-10H-PHENOTHIAZINE-10-PROPANAMINE |
(2R)-3-(2-METHOXYPHENOTHIAZIN-10-YL)-N,N,2-TRIMETHYL-PROPAN-1-AMINE |
LEVOMEPRAZINE|||LEVOMEPROMAZIN|||LEVOPROMEHAZINE|||NEOZINE|||NIRVAN |
D00403 |
C07192 |
AB00514679 |
PL061791 |
PL006275 |
NCGC00179370-01 |
LEVOMEPROMAZINE [USAN:INN:BAN:DCF] |
BDBM50418049 |
ZINC20246 |
PHENOTHIAZINE, 10-(3-(DIMETHYLAMINO)-2-METHYLPROPYL)-2-METHOXY-, (-)- |
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-METHOXY-N,N,BETA-TRIMETHYL-, (R)- |
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-METHOXY-N,N,BETA-TRIMETHYL-, (BETAR)- |
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-METHOXY-N,N,BETA-TRIMETHYL-, (-)- |
GTPL7603 |
BPBIO1_001028 |
SPBIO_002873 |
BSPBIO_000934 |
SCHEMBL25462 |
LEVOMEPROMAZINE (USAN/INN) |
AC1Q57ZP |
AC1L2HS7 |
9G0LAW7ATQ |
PRESTWICK3_000797 |
PRESTWICK2_000797 |
PRESTWICK1_000797 |
PRESTWICK0_000797 |
7104-38-3 |
LEVOPROME (TN) |
7044 R.P. |
CL 53212 |
[(2R)-3-(2-METHOXY-10H-PHENOTHIAZIN-10-YL)-2-METHYLPROPYL]DIMETHYLAMINE |
NSC 226516 |
NSC226516 |
EINECS 200-495-5 |
NOZINANREG |
NOSINANREG |
LEVOPROMEREG |
LEVOMEPROMAZINA [INN-SPANISH] |
LEVOMEPROMAZINUM [INN-LATIN] |
ARC-VI-C-5 |
BAYER 1213 |
CL 39743 |
CL 36467 |
(2R)-3-(2-METHOXY-10H-PHENOTHIAZIN-10-YL)-N,N,2-TRIMETHYLPROPAN-1-AMINE |
(2R)-3-(2-METHOXYPHENOTHIAZIN-10-YL)-N,N,2-TRIMETHYLPROPAN-1-AMINE |
METHOXYTRIMEPRAZINE |
VERACTIL |
NOMIZAN |
NOCINAN |
NIRNAMINE |
LEVOTOMIN |
HIRNAMINE |
DEDORAN |
LEVOPROMAZIONI |
METHOTRIMEPRAZINE [USP] |
METHOTRIMEPRAZINE (USP) |
MINOZINAN |
MILEZIN |
CHEBI:6838 |
NEOZINE |
UNII-9G0LAW7ATQ |
72287 |
FDA Approval | not approved by the FDA |
Drug Class | small molecule |
Drug Indications | Antipsychotic Agents |
Year of Approval | not approved by the fda |
Drug Class | antipsychotic agents |
Drug Categories | tranquilizing agents |
Drug Categories | therapeutic uses |
Drug Categories | sulfur compounds |
Drug Categories | sensory system agents |
Drug Categories | qtc-prolonging agents (indeterminate risk and risk modifying) |
Drug Categories | psychotropic drugs |
Drug Categories | psycholeptics |
Drug Categories | physiological effects of drugs |
Drug Categories | phenothiazines with aliphatic side-chain |
Drug Categories | phenothiazines |
Drug Categories | pharmacologic actions |
Drug Categories | peripheral nervous system agents |
Drug Categories | organic chemicals |
Drug Categories | neurotransmitter agents |
Drug Categories | nervous system |
Drug Categories | molecular mechanisms of pharmacological action |
Drug Categories | inorganic chemicals |
Drug Categories | hyperglycemia-associated agents |
Drug Categories | heterocyclic compounds, 3-ring |
Drug Categories | heterocyclic compounds |
Drug Categories | dopamine antagonists |
Drug Categories | dopamine agents |
Drug Categories | cytochrome p-450 cyp2e1 inhibitors |
Drug Categories | cytochrome p-450 cyp2d6 substrates |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (strong) |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors |
Drug Categories | chemical actions and uses |
Drug Categories | central nervous system depressants |
Drug Categories | central nervous system agents |
Drug Categories | antipsychotic agents (first generation [typical]) |
Drug Categories | antipsychotic agents |
Drug Categories | analgesics, non-narcotic |
Drug Categories | analgesics |
Drug Categories | alpha1 antagonists |
Drug Groups | approved |
Drug Type | small molecule |
antagonist |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
antagonist |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
antagonist |
antagonist |
antagonist |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
antagonist |
antagonist |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
Trial Name | - |
Novel drug target | Established target |
antagonist |
antagonist |
antagonist |
n/a |
Trial Name | - |
Novel drug target | Established target |
METHOTRIMEPRAZINE | DrugBank Drug Name |
(-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine | Drug Synonym |
(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine | Drug Synonym |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | alpha1 antagonists |
METHOTRIMEPRAZINE | Primary Drug Name |
Drug Class | antipsychotic agents |
Year of Approval | not approved by the fda |
Drug Indications | Antipsychotic Agents |
Drug Class | small molecule |
FDA Approval | not approved by the FDA |
LEVOMEPROMAZINE | pubchem_primary_name |
72287 | PubChem CID |
METHOTRIMEPRAZINE | Drug Synonym |